首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients.
【24h】

Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients.

机译:聚乙二醇干扰素-α-2a和利巴韦林在HIV / HCV合并感染患者中的功效研究中,胰岛素抵抗预示治疗失败。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND & AIMS: Few studies evaluated the efficacy of HCV re-treatment and the predictors of response in HIV/HCV co-infected patients. The role of insulin resistance as a predictor of response in this population is unknown. The aim of this study is to evaluate the safety and efficacy of pegylated interferon-alpha-2a and ribavirin in re-treatment of HIV/HCV co-infected patients, predictors of sustained virological response, including insulin resistance, and the relationship between insulin resistance and liver histology. METHODS: This prospective, multi-centered study included HIV/HCV co-infected patients with prior interferon-based treatment failure. Patients received pegylated interferon-alpha-2a and ribavirin for 48 weeks. Serum HCV RNA was measured 24 weeks post treatment to assess sustained virological response. Insulin resistance was defined as HOMA-IR >2. Correlations between baseline insulin resistance and steatosis, and/or cirrhosis were determined. RESULTS: Sustained virological response was achieved in 14/96 (15%) patients. 35% of patients with HOMA-IR < 2 (6/17) achieved sustained virological response vs 14% (5/36) of those with HOMA-IR between 2-4, and 7% (3/41) of those with HOMA-IR > 4 (p = 0.01). In multivariable analysis, insulin resistance and log HCV RNA were negatively associated with sustained virological response [AOR 0.17; 95% CI 0.05-0.64, p = 0.009, and AOR 0.36; 95% CI 0.14-0.93, p = 0.04, respectively]. Steatosis and cirrhosis correlated with insulin resistance (p = 0.02 and 0.03, respectively) but neither independently predicted sustained virological response. Discontinuations due to severe adverse events occurred in 8% of cases, and 2 patients died of unrelated causes. CONCLUSIONS: In HIV/HCV co-infected patients undergoing re-treatment, sustained virological response rate is low; those patients without insulin resistance are significantly more likely to achieve sustained virological response.
机译:背景与目的:很少有研究评估HCV再治疗的有效性以及HIV / HCV合并感染患者的反应预测因子。胰岛素抵抗在该人群中作为反应预测因子的作用尚不清楚。这项研究的目的是评估聚乙二醇化干扰素-α-2a和利巴韦林在HIV / HCV合并感染患者的再治疗中的安全性和有效性,持续的病毒学应答(包括胰岛素抵抗)的预测因子以及胰岛素抵抗之间的关系和肝脏组织学。方法:这项前瞻性,多中心研究纳入了既往以干扰素为基础治疗失败的HIV / HCV合并感染患者。患者接受聚乙二醇化干扰素-α-2a和利巴韦林治疗48周。治疗后24周测量血清HCV RNA,以评估持续的病毒学应答。胰岛素抵抗定义为HOMA-1R> 2。确定了基线胰岛素抵抗与脂肪变性和/或肝硬化之间的相关性。结果:14/96(15%)患者获得了持续的病毒学应答。 35%的HOMA-IR <2(6/17)患者获得了持续的病毒学应答,而14%(5/36)的HOMA-IR患者为2-4,而7%(3/41)的患者为HOMA-IR -IR> 4(p = 0.01)。在多变量分析中,胰岛素抵抗和log HCV RNA与持续的病毒学应答呈负相关[AOR 0.17; 95%CI 0.05-0.64,p = 0.009,AOR 0.36; 95%CI 0.14-0.93,p = 0.04]。脂肪变性和肝硬化与胰岛素抵抗相关(分别为p = 0.02和0.03),但均未独立预测持续的病毒学应答。 8%的病例因严重不良事件而中断治疗,2例患者死于无关原因。结论:在接受再次治疗的HIV / HCV合并感染患者中,持续的病毒学应答率很低。那些没有胰岛素抵抗的患者更有可能获得持续的病毒学应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号